Akèy › Adenokasinom Ezofajyen › Kalifòni › Los Angeles
Etid klinik pou Adenokasinom Ezofajyen nan Los Angeles, CA
9 etid pou Adenokasinom Ezofajyen ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Ap rekriteFaz 2/3
- Keck Medicine of USC Koreatown, Los Angeles
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- ak 3 plis
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Ap rekriteFaz 3
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Ap rekriteFaz 2/3
- USC/Norris Comprehensive Cancer Center, Los Angeles
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Ap rekriteFaz 1/2
- Ellison Medical Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
- University of California Los Angeles, Los Angeles
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
Ap rekrite
- University of California, Los Angeles, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
- Los Angeles Cancer Network, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
Ap rekrite
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Etid Adenokasinom Ezofajyen nan lòt vil
- New York City, NY18 etid
- Boston, MA13 etid
- Houston, TX12 etid
- Nashville, TN11 etid
- Arlington, VA11 etid
- Durham, NC10 etid
- Jacksonville, FL9 etid
- Baldwin Park, CA9 etid
- Rochester, MN9 etid
- St. Louis, MO9 etid
- Queens, NY9 etid
- Dallas, TX8 etid
Lòt etid nan Los Angeles
- Kansè Poumon ki pa ti selil87 etid
- Kansè (tout kalite)74 etid
- Kansè nan tete73 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè ovè50 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.